Get 40% Off
👀 👁 🧿 All eyes on Biogen, up +4,56% after posting earnings. Our AI picked it in March 2024.
Which stocks will surge next?
Unlock AI-picked Stocks

Oldest patient yet cured of HIV after stem cell transplant – researchers

Published 27/07/2022, 19:33
Updated 27/07/2022, 19:41
© Reuters. FILE PHOTO - A digitally colorized scanning electron microscopic image depicts a single, red colored H9-T cell that had been infected by numerous, spheroid shaped, mustard colored human immunodeficiency virus (HIV) particles attached to the cell's surface

By Jennifer Rigby

LONDON (Reuters) - The oldest patient yet has been cured of HIV after receiving a stem cell transplant for leukaemia, researchers reported on Wednesday.

While the transplant was planned to treat the now-66-year-old's leukaemia, the doctors also sought a donor who was naturally resistant to the virus that causes AIDS, a mechanism that first worked to cure the "Berlin patient", Timothy Ray Brown, in 2007.

The latest patient, the fourth to be cured in this way, is known as the "City of Hope" patient after the U.S. facility in Duarte, California, where he was treated, because he does not want to be identified.

As well as being the oldest, the patient has also had HIV the longest, having been diagnosed in 1988 with what he described as a "death sentence" that killed many of his friends.

He has been on antiretroviral therapy (ART) to control his condition for more than 30 years.

Doctors who presented the data ahead of the International Aids Society's (IAS) 2022 meeting said the case opened up the potential for older patients with HIV and blood cancer to access the treatment, particularly as the stem cell donor was not a family member.

HOPE

Describing a cure as the "holy grail", Sharon Lewin, president-elect of the IAS, said the case provided "continued hope ... and inspiration" for people with HIV and the wider scientific community, although it was unlikely to be an option for most people with HIV due to the risks of the procedure.

3rd party Ad. Not an offer or recommendation by Investing.com. See disclosure here or remove ads .

Scientists think the process works because the donor individual's stem cells have a specific, rare genetic mutation which means they lack the receptors used by HIV to infect cells.

After the transplant three and a half years ago, which followed chemotherapy, the City of Hope patient stopped taking ART in March 2021. He has now been in remission from both HIV and leukaemia for more than a year, the team said.

On Wednesday, researchers in Spain also presented details of a 59-year-old woman who is one of a rare group of what is known as "post-treatment controllers". They can maintain undetectable viral loads after stopping ART, and also provide clues to a potential cure, Lewin said.

Ahead of the IAS conference that starts on Friday, the Joint United Nations Programme on HIV/AIDS (UNAIDS) also presented data showing how the COVID-19 pandemic had derailed global efforts to tackle HIV, including a reversal of progress in the world's most populous region, Asia and the Pacific.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.